Royalty Payment Term. Subject to the cumulative royalty cap specified in Section 8.07.6, ExxonMobil's obligation to pay license royalties to Symyx Tech shall continue for each Royalty-Bearing Product until *.
Royalty Payment Term. “Royalty Payment Term” shall have the meaning assigned to such term in the Royalty Agreement.
Royalty Payment Term. The obligations of GSK to calculate and make royalty payments as set forth in Section 8.3 above will commence upon the First Commercial Sale of the Licensed Product in the Territory by GSK, its Affiliates, sublicensees or Excluded Distributors and will continue for the Term.
Royalty Payment Term. The obligation of Licensee to make payments under Sections 4.1 and 4.2 shall continue, on a Licensed Product-by-Licensed Product and country-by-country basis, until the later of (i) the date on which the offering for sale, selling, making, having made, using, or importing such Licensed Product is no longer covered by a Valid Claim of a Licensed Patent in such country and (ii) the 15th anniversary of the first commercial sale of such Licensed Product in such country. [****] The following portion has been omitted pursuant to a Confidential Treatment Request under Rule 24b-2 of the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.
Royalty Payment Term. The obligation of Purchaser to make payments under Sections 3.1 and 3.2 shall continue, on a Product-by-Product and country-by-country basis, until the 15th anniversary of the first commercial sale of such Product in such country.
Royalty Payment Term. Pfizer shall pay Isis a royalty based on the Net Sales of each Licensed Product.
Royalty Payment Term. The above royalties shall be payable from the Transition Date until the [* * *] anniversary of the Transition Date (the “Royalty Term”), irrespective of [* * *]. By way of illustration, [* * *].
Royalty Payment Term. The above royalties shall be payable for each Product in each country of the Sanofi Territory until the later to occur of (i) the expiration of the last to expire Valid Claim within the Vivus Patents that, absent the licenses granted to Sanofi hereunder, would be infringed by the sale of such Product in such country, and (ii) the sixteenth anniversary of the Effective Date (the “Royalty Payment Term”).
Royalty Payment Term. Payment term will begin with the effective date of the first royalty payment as expressed in Article 6 and continue for a period of seven additional years after which time payments will cease
Royalty Payment Term. Immunic’s obligation to make royalty payments terminates on a country-by-country and Licensed Product-by-Licensed Product basis by the later of (i) the Licensed Product is no longer covered by a Valid Claim in an issued patent within the DS Patent Rights in the relevant country, or (ii) [***] after the First Commercial Sale of the respective Licensed Product in the relevant country; provided, however, that if the Licensed Product:
